Table 2.
Demographics and characteristics of patient in the training and validation cohorts.
| Training cohort (n = 282) | Validation cohort (n = 122) | P-value | |
|---|---|---|---|
| Age | 0.8545 | ||
| ≥60 | 157 (55.67%) | 66 (54.10%) | |
| <60 | 125 (44.33%) | 56 (45.90%) | |
| Gender | 0.3792 | ||
| Male | 221 (78.37%) | 90 (73.77%) | |
| Female | 61 (21.63%) | 32 (26.23%) | |
| ECOG-PS | 0.979 | ||
| 0 | 169 (59.93%) | 74 (60.66%) | |
| 1 | 113 (40.07%) | 48 (39.34%) | |
| Smoking status | 0.5983 | ||
| Never | 39 (13.83%) | 19 (15.57%) | |
| Former | 90 (31.91%) | 41(33.61%) | |
| Active | 153 (54.26%) | 62 (50.82%) | |
| Location | 0.0703 | ||
| Right | 156 (55.32%) | 80 (65.57%) | |
| Left | 126 (44.68%) | 42 (34.43%) | |
| Pathologic subtype | 0.8148 | ||
| Uncommon pathological subtype | 34 (12.06%) | 13 (10.66%) | |
| Common pathological subtype | 248 (87.94%) | 109 (89.34%) | |
| Stage | 0.9742 | ||
| Stage III | 35 (12.41%) | 16 (13.11%) | |
| Stage IV | 247 (87.59%) | 106 (86.89%) | |
| PDL1:TPS | 0.6293 | ||
| <1% | 62 (21.99%) | 28 (22.95%) | |
| 1–49% | 73 (25.89%) | 34 (27.87%) | |
| ≥50% | 60 (21.28%) | 30 (24.59%) | |
| Unknown | 87 (30.85%) | 30 (24.59%) | |
| Line of treatments | 0.4339 | ||
| 1st | 144 (51.06%) | 67 (54.92%) | |
| 2nd | 89 (31.56%) | 40 (32.79%) | |
| ≥3rd | 49 (17.38%) | 15 (12.30%) | |
| Treatment | 0.9999 | ||
| Monotherapy | 111 (39.36%) | 48 (39.34%) | |
| Combination | 171 (60.64%) | 74 (60.66%) |